NT 10-Q 1 chinayongxin_ext.htm CHINA YONGXIN chinayongxin_ext.htm
Washington, D.C. 20549
FORM 12b-25
SEC FILE NUMBER:  000-26293
CUSIP NUMBER:  16946Y 108

(Check One):  Form 10-K [_]   Form 20-F [_]    Form 11-K [_]
Form 10-Q [X]    Form 10-D [_]    Form N-SAR [_]    Form N-CSR [_]

For Period Ended:  March 31, 2008
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
For the Transition Period Ended:  ___________________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
China Yongxin Pharmaceuticals Inc.                                                                                                

Full Name of Registrant
Nutradyne Group, Inc.                                                                                     
Former Name if Applicable:
927 Canada Court                                                                                     
Address of Principal Executive Office (Street and Number)
City of Industry, California 91748                                                                                     
City, State and Zip Code


PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period.
The Registrant could not prepare, review, and complete its Quarterly Report on Form 10-Q without incurring unreasonable effort and expense in connection with accurately preparing and presenting all necessary disclosures.  The Registrant will file its Quarterly Report on Form 10-Q as soon as possible, and in any event no later than the fifth calendar day following the prescribed due date for such report.
(1) Name and telephone number of person to contact in regard to this notification

Samuel Liu
(Area Code)
(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes [_]  No [X]
The financial statements required by Item 9.01 have not been filed with respect to the Company's Current Report on Form 8-K originally filed on November 26, 2007.
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes [_]  No [X]
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

China Yongxin Pharmaceuticals Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  May 15, 2008                                                                          
By: /s/  Samuel Liu        
Name:  Samuel Liu
Title: President and Chief Operating Officer